41–50 of 172 posts
Much-needed Outline.com of the article: https://outline.com/MJaPqX Wired.com is almost literally unreadable. It's a caricature of all that's wrong with modern web design. Is everyone else seeing what I'm seeing? http://u.cubeupload.com/temp9871/wired.png
Not quite - you forgot the GDPR popup on top of the subscribe popup, as well as the autoplaying video ad with sound!
Much-needed Outline.com of the article: https://outline.com/MJaPqX Wired.com is almost literally unreadable. It's a caricature of all that's wrong with modern web design. Is everyone else seeing what I'm seeing? http://u.cubeupload.com/temp9871/wired.png
I recently got into the habit of swinging Firefox's reader view ( https://support.mozilla.org/en-US/kb/firefox-reader-view-clu... ) on a hair trigger. A single click on any of my devices, it cuts an awesome swathe through the internet jungle. For now.
There is no news I enjoy reading more than that a clinical trial had to be ended early because the treatment was so effective that it would be unethical to continue with alternative treatments (or a placebo).
There is no news I enjoy reading more than that a clinical trial had to be ended early because the treatment was so effective that it would be unethical to continue with alternative treatments (or a placebo).
Actually, it's quite terrifying when you remember that stopping a clinical trial early is a great way to create statistical fraud. https://blogs.sciencemag.org/pipeline/archives/2019/08/08/st... cites an example of a drug whose clinical trial was stopped early due to obviously effective success... only to discover later on that the "obviously effective" was a statistically spurious event, and the drug did not confer…
Additionally, my understanding from a quick read is that the SPMS trials were aiming to delay progression in disability, rather than eliminate the effects altogether. That seems trickier to measure, and also more subject to just... not spending enough time looking at it.
Ebola, on the other hand, has a binary outcome (dead vs cured) with a timeline of a couple weeks, IIRC.
There is no news I enjoy reading more than that a clinical trial had to be ended early because the treatment was so effective that it would be unethical to continue with alternative treatments (or a placebo).
Actually, it's quite terrifying when you remember that stopping a clinical trial early is a great way to create statistical fraud. https://blogs.sciencemag.org/pipeline/archives/2019/08/08/st... cites an example of a drug whose clinical trial was stopped early due to obviously effective success... only to discover later on that the "obviously effective" was a statistically spurious event, and the drug did not confer…
> the reason the first trial came to an exaggerated impression seemed to be the number of patients who might not have fully progressed to SPMS
Stopping early can lead to statistical fraud, which is why the bar is so high on doing so. But it has to be balanced with the recognition that, if the interim results are correct, continuing the trial will lead to a significant number of avoidable deaths.
And for what it's worth, given the believed cause of the flawed trial being cited, it sure sounds like if the trial had run to its conclusion it still would have produced flawed results.
I want to know how long it will take for Ebola to evolve a resistance to this therapy.
> I want to know how long it will take for Ebola to evolve a resistance to this therapy. Maybe never. A lot of time in any case, probably. Ebola is a plant's virus adapted to trees. Evolved to use bats (and probably arboreal snakes also) but can't survive for a long time in primates, and can't survive in soil at long term. We are a dead end for it. Would need infected humans munching some inedible leaves of a tropica…
What is notable about Ebola is that its virulence keeps dropping while its ability to spread has significantly increased. The larger issue is that Ebola is in areas that don't have the resources to handle any serious outbreak. It's becoming more likely that Ebola is going to be self sustaining soon.
I'm kind of amazed that a comment expressing interest in when this therapy will be obsolete, see that 96% of bacteria are resistant to Penicillin G now, gets a negative response. Drugs are only effective when the pathogen is still sensitive to them.
There is no news I enjoy reading more than that a clinical trial had to be ended early because the treatment was so effective that it would be unethical to continue with alternative treatments (or a placebo).
Actually, it's quite terrifying when you remember that stopping a clinical trial early is a great way to create statistical fraud. https://blogs.sciencemag.org/pipeline/archives/2019/08/08/st... cites an example of a drug whose clinical trial was stopped early due to obviously effective success... only to discover later on that the "obviously effective" was a statistically spurious event, and the drug did not confer…
It's great news, but they're observing a 30% mortality rate for the "cure". Absent medical intervention there is still a nontrivial survival rate (mortality rate of 75-90%). With supporting medical treatment before this new treatment - fluid support, etc - I think it's up to 50%? It sounds like the monoclonal antibody treatment has improved odds of survival from 1:10-1:2 to 2:3. edit: The 6% figure is population rest…